文献速递呼吸衰竭与机械通气儿科与产科急症重症综合管理与镇静镇痛

妊娠合并重症ARDS行ECMO救治后的分娩决策:一项回顾性多中心队列研究

Delivery decision in pregnant women rescued by ECMO for severe ARDS: a retrospective multicenter cohort study.
PubMed 文献 · Crit Care · 2022-10-17
一句话结论ECMO支持期间继续妊娠显著增加胎儿死亡风险,但存活新生儿早产相关疾病较少,产妇结局无差异;分娩时机应由有经验的ECMO中心多学科团队定期评估。

该多中心回顾性队列纳入2009年10月至2021年8月四家ECMO中心因重症ARDS接受ECMO支持的危重孕妇(妊娠中或旨在挽救母/儿的产后15天内)共24例,比较ECMO插管前(继续妊娠)与插管后(急诊分娩后)做出分娩决策的两组母婴短期和长期结局。继续妊娠组11例在妊娠中位25(21-29)周插管,产后组13例在妊娠中位32(17-39)周急诊分娩后插管,ECMO前PaO2/FiO2为57(26-98)且两组无差异。产后组大出血更多(46% vs 18%,p=0.05),产妇院内生存率88%且两组无差异;继续妊娠组4例(36%)在ECMO上发生自然流产,产后组胎儿生存率更高(92% vs 55%,p=0.03),存活新生儿未报告严重早产疾病或远期后遗症。结论提示ECMO支持期间继续妊娠显著增加胎儿死亡风险,但改善存活新生儿的早产相关疾病,产妇结局无差异,分娩时机、地点和方式应由有经验的ECMO中心多学科团队决定并定期重新评估。

要点

  • 继续妊娠组胎儿生存率55% vs 产后ECMO组92%,产后组更高(p=0.03),继续妊娠组4例(36%)在ECMO上自然流产。
  • 产后ECMO组大出血发生率46% vs 继续妊娠组18%(p=0.05),产后组更多。
  • 产妇院内生存率总体88%,继续妊娠组与产后组无差异。
  • ECMO前PaO2/FiO2中位57(26-98),两组无差异。
  • 存活新生儿中未报告严重早产疾病或远期后遗症。

适用人群与场景

  • 妊娠中或旨在挽救母/儿的产后15天内、因重症ARDS接受ECMO支持的危重孕妇,来自四家ECMO中心,2009年10月至2021年8月。

处置流程与药物剂量

  • 分娩时机、地点和方式应由有经验的ECMO中心多学科团队决定并定期重新评估(作者建议)。

研究设计与关键结果

  • 研究类型:多中心回顾性队列,四家ECMO中心,共纳入24例(继续妊娠组11例,产后ECMO组13例)。
  • 继续妊娠组11例在妊娠中位25(21-29)周插管;产后ECMO组13例在妊娠中位32(17-39)周急诊分娩后插管。
  • ECMO前PaO2/FiO2中位57(26-98),两组无差异。
  • 产后ECMO组大出血46% vs 继续妊娠组18%(p=0.05)。
  • 产妇院内生存率88%,两组无差异。
  • 继续妊娠组4例(36%)在ECMO上发生自然流产。
  • 胎儿生存率产后ECMO组92% vs 继续妊娠组55%(p=0.03)。
  • 存活新生儿中未报告严重早产疾病或远期后遗症。

证据类型、等级与局限

  • 证据类型:多中心回顾性队列研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • ECMO支持期间继续妊娠显著增加胎儿死亡风险,但改善存活新生儿的早产相关疾病,产妇结局无差异。
  • 作者建议:分娩时机、地点和方式应由有经验的ECMO中心多学科团队决定并定期重新评估。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Although rarely addressed in the literature, a key question in the care of critically pregnant women with severe acute respiratory distress syndrome (ARDS), especially at the time of extracorporeal membrane oxygenation (ECMO) decision, is whether delivery might substantially improve the mother's and child's conditions. This multicenter, retrospective cohort aims to report maternal and fetal short- and long-term outcomes of pregnant women with ECMO-rescued severe ARDS according to the timing of the delivery decision taken before or after ECMO cannulation.

METHODS: We included critically ill women with ongoing pregnancy or within 15 days after a maternal/child-rescue-aimed delivery supported by ECMO for a severe ARDS between October 2009 and August 2021 in four ECMO centers. Clinical characteristics, critical care management, complications, and hospital discharge status for both mothers and children were collected. Long-term outcomes and premature birth complications were assessed.

RESULTS: Among 563 women on venovenous ECMO during the study period, 11 were cannulated during an ongoing pregnancy at a median (range) of 25 (21-29) gestational weeks, and 13 after an emergency delivery performed at 32 (17-39) weeks of gestation. Pre-ECMO PaO2/FiO2 ratio was 57 (26-98) and did not differ between the two groups. Patients on ECMO after delivery reported more major bleeding (46 vs. 18%, p = 0.05) than those with ongoing pregnancy. Overall, the maternal hospital survival was 88%, which was not different between the two groups. Four (36%) of pregnant women had a spontaneous expulsion on ECMO, and fetal survival was higher when ECMO was set after delivery (92% vs. 55%, p = 0.03). Among newborns alive, no severe preterm morbidity or long-term sequelae were reported.

CONCLUSION: Continuation of the pregnancy on ECMO support carries a significant risk of fetal death while improving prematurity-related morbidity in alive newborns with no difference in maternal outcomes. Decisions regarding timing, place, and mode of delivery should be taken and regularly (re)assess by a multidisciplinary team in experienced ECMO centers.

来源:Crit Care,查看原文。版权归原作者所有。

参考来源

  1. Aissi James S, Guervilly C, Lesouhaitier M, et al. Delivery decision in pregnant women rescued by ECMO for severe ARDS: a retrospective multicenter cohort study. Crit Care. 2022. PMID: 36253839. doi:10.1186/s13054-022-04189-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。